PTC Therapeutics
PTC Therapeutics Inc is a commercial-stage biopharmaceutical enterprise headquartered in South Plainfield, New Jersey. The company focuses on the discovery, development, and commercialization of orally administered medicines targeting rare genetic disorders and oncology conditions. Its clinical pipeline and commercial portfolio feature therapeutic products addressing nonsense mutation genetic diseases, spinal muscular atrophy, and rare rare metabolic conditions. Principal revenue is derived through direct commercial pharmaceutical sales, government health agency supply agreements, and licensing royalties. The enterprise serves patients globally. PTC Therapeutics Inc is publicly traded on the Nasdaq Stock Market.
9 of the funds FundTelligence covers report a position in PTC Therapeutics.
- Legal name
- PTC Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 9
Funds holding PTC Therapeutics
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.54 % (full portfolio disclosed, September 2026)
- BNP US Small Cap — BNP Paribas · 0.86 % (full portfolio disclosed, June 2026)
- JPM Global Healthcare Fund — JPM · 0.61 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.53 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.35 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.06 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.05 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.05 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 9 funds holding it.